SEPN Septerna Inc: Price-to-Projected Revenue Ratio
Septerna Inc is accelerating the development of immunological agents via its Native GPCR robotic system. The projected P/S trend helps align market capitalization with expected revenue, where 20.60 is established as the baseline value. An innovative approach to GPCR targets strengthens the company's authority within the scientific community. A neutral geopolitical backdrop and the business's humanitarian profile minimize external risks for investors.
Analytical breakdowns for Septerna Pharma (SEPN)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Septerna Inc|SEPN - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Septerna Inc|SEPN - Company Cumulative Debt|Debt to Book Capitalization Ratio Septerna Pharma|SEPN - Company Long-Term Loans and Borrowings|Company Short-Term Debt Septerna|Quick Ratio septerna.com
- financial results and valuation multiples details:
SEPN - Net Profit|Future Profit Septerna Inc|SEPN - Company Value to Net Income|Forward P/E Multiple Septerna Corp|SEPN - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Septerna Pharma|SEPN - Operating profit before amortization|Net earnings per share (EPS TTM) Septerna|SEPN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months septerna.com|SEPN - Expected net earnings per share growth this year|Earnings growth forecast for next year Septerna Inc
- revenue and sales details:
Initial company analysis:SEPN (Septerna)
Septerna Inc (SEPN) maintains stability by retaining leading GPCR receptor specialists through a stock option system. The forward P/S multiple daily compares market capitalization with expected revenue, reflecting the business value trend. Extremes on this chart signal a disconnect between model viability and capital risk, allowing investors to determine the asset's fair value based on the commercialization prospects of its developments.
Key competitors
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio ADMA Corp ADMA|PTGX: Forward P/S Multiple|Market Cap to Future Revenue Ratio immunovant.com (IMVT)|Price-to-Projected Revenue Ratio Kiniksa|Grifols SA - Future Price to Revenue|Forward Price-to-Revenue Multiple ADPT (Adaptive Biotechnologies Corp)|Price to Expected Revenue Ratio CLDX|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|biocryst.com (BCRX) - Market Cap to Future Revenue Ratio|VERA - Price-to-Projected Revenue Ratio|Forward Price to Sales DNTH (Dianthus Therapeutics Inc)|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ABCL|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|Forward P/S Multiple precigen.com|Forward Price-to-Revenue Multiple PHAR (Pharming Group)|NKTR (Nektar Therapeutics Inc) - Forward Price to Sales|Forward P/S Multiple UPB (Upstream Bio Corp)|Market Cap to Expected Sales Ratio Zenas Corp (ZBIO)|IMNM - Price-to-Projected Revenue Ratio|GOSS (gossamerbio.com) - Market Cap to Projected Revenue|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pieris Pharma|Price-to-Projected Revenue Ratio Savara Corp|Rigel Corp (RIGL) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ANAB|ATXS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio enGene ENGN|RAPT (RAPT Therapeutics Inc.) - Future Price to Revenue|JBIO - Price-to-Projected Revenue Ratio|ACRS (Aclaris Therapeutics, Inc) - Market Cap to Projected Revenue|Kyverna Therapeutics (KYTX) - Price-to-Projected Revenue Ratio|Future Price to Revenue TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - Forward P/S Multiple|VTYX: Forward Price to Sales|Forward P/S Multiple THTX|Forward P/S Multiple Avalo Therapeutics Inc (AVTX)|Price-to-Projected Revenue Ratio Eledon Pharmaceuticals ELDN|Forward Price to Sales AGEN|CLYM - Price-to-Projected Revenue Ratio|Zura Bio Ltd (ZURA) - Forward Price-to-Revenue Multiple|ATYR: Forward P/S Multiple|Adagene Inc. (ADAG) - Forward P/S Multiple|Forward Price-to-Revenue Multiple IMA|STTK: Forward Price to Sales|Forward P/S Multiple EQ|Market Cap to Expected Sales Ratio connectbiopharm.com|Price-to-Projected Revenue Ratio Immunic IMUX|ATRA - Forward Price-to-Revenue Multiple|IFRX - Price-to-Projected Revenue Ratio|x4pharma.com (XFOR) - Forward Price-to-Revenue Multiple|ACET (adicetbio.com) - Forward Price-to-Revenue Multiple|Celularity (CELU) - Forward P/S Multiple|Price-to-Projected Revenue Ratio INmune Bio Corp|Market Cap to Projected Revenue BRNS (Barinthus Biotherapeutics Corp)|Forward P/S Multiple KZR|SABS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Akari Therapeutics Plc AKTX|Market Cap to Expected Sales Ratio Enlivex Therapeutics Ltd (ENLV)|Q32 Bio Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio GeoVax Corp|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|Future Price to Revenue IBIO (ibioinc.com)|Forward Price-to-Revenue Multiple CARM|XTLB (XTL Biopharmaceuticals Ltd) - Price to Expected Revenue Ratio|Forward P/S Multiple BOLT|HCWB - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|Forward Price to Sales AIM|ADTX - Price-to-Projected Revenue Ratio|GRI (GRI Bio Inc) - Market Cap to Projected Revenue|XRTX: Forward P/S Multiple|Vyome Therapeutics (HIND) - Forward P/S Multiple|Forward Price-to-Revenue Multiple REVB|INDP: Forward Price to Sales|Forward P/S Multiple SCNI|Market Cap to Expected Sales Ratio calcimedica.com|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|ALLK: Market Cap to Projected Revenue|HOOKIPA - Forward P/S Multiple|IGM Biosciences, Inc. (IGMS) - Forward Price-to-Revenue Multiple|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|OCEA - Market Cap to Expected Sales Ratio|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Third Harmonic Bio Inc THRD
